1. Introduction
Recent findings have confirmed the therapeutic properties of human milk components and have left no doubt that it constitutes an indispensable part of newborns’ nutritional treatment, especially premature babies with very low (VLBW) and extremely low (ELBW) birth weight. Initiating lactation in preterms’ mothers and maintaining mother’s milk supply for NICU infants remains challenging. Donor milk has become the standard way of feeding newborns who cannot receive the milk of their biological mothers [
1]. Donor milk administration to prematurely born children needing longer hospital stays requires necessary collecting procedures, freezing, storage and pasteurization. This may considerably lower its nutritional and therapeutic values. So far, the best characterized and commonly used method of human milk preservation is holder pasteurization. However, the knowledge about the significant negative impacts of this method on the active components in human milk results in the development of novel techniques that could better preserve nutritional and non-nutritional factors.
The aim of this narrative review was to analyze the best characterized and current methods of human milk processing in the context of minimizing qualitative and quantitative losses of its bioactive elements and ensuring safety in clinical situations.
2. Materials and Methods
The literature review included electronic searches of MEDLINE (January 2000–January 2019), EMBASE (January 2000–January 2019) and conference proceedings. The electronic search used the following text words and MeSH terms: donor milk, human milk, breast milk, banked milk, (human milk OR donor milk) AND pasteurization [–] (human milk OR breast milk) AND, preservation (human milk OR breast milk) AND holder pasteurization (human milk OR breast milk) AND, high-pressure (human milk OR breast milk), UV–treatment (human milk OR breast milk), microwave (human milk OR breast milk). Reference lists of the previous reviews and relevant studies were examined. Research that had been reported only as abstracts were eligible for inclusion if sufficient information was available from the report.
3. Results and Discussion
Microbiological safety is the primary criterion that has to be fulfilled as far as food for newborns is concerned. Therefore, firstly we focus on the effectiveness of the proposed human milk processing methods in human milk pathogen elimination ().
Table 1. Studies of Holder Pasteurization, High-Temperature Short-Time, High Pressure Processing and Microwave Irradiation HoP, HTST, HPP, MI on microbiological and viral components of human milk.
Tested Component |
HoP |
HTST |
HPP |
MI |
References |
Bacteriostatic effect on E.coli and L. innocua |
48% reduction 28% reduction |
64% reduction 39% reduction |
not studied |
not studied |
[5,6] |
Inactivation of selected microorganisms (L. monocytogenes S. agalactiae, E. coli, S. aureus) |
inactivation |
not studied |
inactivation |
not studied |
[7] |
Inactivation of selected microorganisms (Enterobacteriaceae) |
inactivation |
not studied |
inactivation |
not studied |
[8] |
Inactivation of selected microorganisms (S. aureus ATCC 6538, Enterobacteriaceae) |
not studied |
not studied |
inactivation |
not studied |
[9] |
Antibacterial efficacy (Coagulase-negative staphylococci, Gram- negative bacteria, Enterococcus species) |
reduced bacterial counts |
reduced bacterial counts |
not studied |
not studied |
[10] |
Microbiological quality (vegetative forms of microorganisms present in raw milk samples) |
destroyed commensal and contaminant vegetative microorganisms except Bacillus sp. |
destroyed all vegetative forms of microorganisms except Bacillus sp. and E. faecalis |
not studied |
not studied |
[11] |
Inactivation of selected microorganisms (S.aureus) |
inactivation |
not studied |
inactivation |
not studied |
[12] |
Inactivation of selected microorganisms (S.aureus, B. cerues) |
partial inactivation |
not studied |
inactivation |
not studied |
[13] |
Inactivation of selected microorganisms (E.coli, P. aeruginosa, S. aureus, S. epidermidis) |
inactivation |
not studied |
not studied |
inactivation |
[14] |
Ebola Virus |
inactivation |
not studied |
not studied |
not studied |
[15] |
Marburg Virus |
inactivation |
not studied |
not studied |
not studied |
[15] |
Zika virus |
inactivation |
not studied |
not studied |
not studied |
[16] |
CMV |
Inactivation destroy viral infectivity |
destroy viral infectivity |
not studied |
inactivation |
[17,18,19] |
HTLV HIV |
inactivation |
inactivation |
not studied |
not studied |
[20] |
HPV high-risk (types 16 and 18), low-risk (type 6) |
inactivation |
not studied |
not studied |
not studied |
[21] |